Literature DB >> 2208134

Insulin-like growth factor gene expression in human smooth muscle tumors.

T Gloudemans1, I Prinsen, J A Van Unnik, C J Lips, W Den Otter, J S Sussenbach.   

Abstract

A role for insulin-like growth factors (IGF) in autocrine or paracrine growth stimulation of tumor cells has been proposed for tumors of different origins. We have studied IGF gene expression in human uterus smooth muscle (myometrium) and in a panel of benign (leiomyoma) and malignant (leiomyosarcoma) smooth muscle tumors. Using RNA transfer blot analysis we could demonstrate that in smooth muscle tissue and tumors IGF genes are differentially expressed. The mRNA species detected had the same size as reported for IGF mRNAs from other tissues. However, the abundance of the IGF gene transcripts varied from tissue to tissue. The amounts of IGF mRNAs detected in smooth muscle tumors were compared to the levels found in normal smooth muscle. The IGF-I gene was expressed at high levels in normal myometrium and in leiomyomas but appears to be repressed in leiomyosarcomas. Also the IGF-I peptide was detected in myometrium and in leiomyomas, but in leiomyosarcomas the level was substantially lower. The IGF-II gene was expressed at low levels in normal myometrium and leiomyomas but is activated in leiomyosarcomas. With increasing malignancy from the two major IGF-II mRNA species, 6.0 and 4.8 kilobases, in particular the 6.0-kilobase mRNA is produced at higher levels. In conclusion, these data suggest that for IGF-I a role in tumor cell growth is not likely, but probably IGF-II is involved in malignant smooth muscle tumor growth progression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208134

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Genomic imprinting and cancer.

Authors:  J A Joyce; P N Schofield
Journal:  Mol Pathol       Date:  1998-08

Review 2.  Regulation of insulin-like growth factors by antiestrogen.

Authors:  R Winston; P C Kao; D T Kiang
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 3.  Medical treatment of uterine leiomyoma.

Authors:  Mohamed Sabry; Ayman Al-Hendy
Journal:  Reprod Sci       Date:  2012-02-28       Impact factor: 3.060

4.  Polycystic ovary syndrome and risk of uterine leiomyomata.

Authors:  Lauren A Wise; Julie R Palmer; Elizabeth A Stewart; Lynn Rosenberg
Journal:  Fertil Steril       Date:  2007-01-22       Impact factor: 7.329

5.  Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.

Authors:  Sadhna Dhingra; Michelle E Rodriguez; Qi Shen; Xuizhen Duan; Melissa L Stanton; Lei Chen; Rongzhen Zhang; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2010-01-28

Review 6.  Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.

Authors:  Pasquapina Ciarmela; Md Soriful Islam; Fernando M Reis; Peter C Gray; Enrrico Bloise; Felice Petraglia; Wylie Vale; Mario Castellucci
Journal:  Hum Reprod Update       Date:  2011-07-25       Impact factor: 15.610

7.  Structural analysis of the human insulin-like growth factor-II P3 promoter.

Authors:  A M Raizis; M R Eccles; A E Reeve
Journal:  Biochem J       Date:  1993-01-01       Impact factor: 3.857

8.  Innovative oral treatments of uterine leiomyoma.

Authors:  Mohamed Sabry; Ayman Al-Hendy
Journal:  Obstet Gynecol Int       Date:  2012-02-16

Review 9.  Insulin-like growth factors and cancer.

Authors:  V M Macaulay
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

Review 10.  Etiology and pathogenesis of uterine leiomyomas: a review.

Authors:  Gordon P Flake; Janet Andersen; Darlene Dixon
Journal:  Environ Health Perspect       Date:  2003-06       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.